Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs International Business Machines Corp (IBM) Price & Performance

Ginkgo Bioworks Holdings IncTrade
International Business Machines CorpTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs International Business Machines Corp — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.28 (market cap $505.73M), while International Business Machines Corp trades at $235.55 (market cap $224.62B). The key difference: International Business Machines Corp is far larger — about 444.2× Ginkgo Bioworks Holdings Inc's market cap, and International Business Machines Corp pays a 2.84% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.

DNAIBM
Market Cap
$505.73M$224.62B
Sector
HealthTechnology
52-Week High
$16.14$329.23
52-Week Low
$5.48$205.77
Enterprise Value
$607.68M$281.76B
Volume
4,481,527
Dividend Yield
2.84%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.21, down 5.75% today, amid bearish technical signals and weak fundamentals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, with persistent losses and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant sell-side coverage, while technical indicators show strong bearish momentum with support at $7.

DNA faces substantial execution risks as it pivots to autonomous lab services, with negative profitability metrics and declining revenue creating headwinds. The stock's valuation appears stretched relative to fundamentals, though recent earnings beats offer some optimism. Investors should weigh the company's long-term biotech potential against near-term financial challenges.

International Business Machines Corp

IBM trades at $234.91, down 0.59% today, with a mixed technical outlook showing bearish moving averages but bullish overall signals. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results pending. The company secured a $240 million AI deal with Together AI, boosting sentiment, but faces a securities fraud investigation following a 25% stock drop. Fundamentals are solid with revenue growth to $67.54 billion in 2025 and a net income margin of 15.52%, though cash flow turned negative.

Outlook is cautiously optimistic with a consensus price target of $257.38, implying 9.6% upside, supported by AI and cloud growth. Risks include the ongoing fraud probe, competitive pressures, and high debt levels. Investors should weigh strong profitability against legal and execution uncertainties in a volatile market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About International Business Machines Corp

International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.

Read more on IBM